Tag Archives: Antidepressant

12-year old’s suicide while on antidepressant highlights alarming rise in psychiatric drugging of military kids

Before his father deployed to Iraq, Daniel Radenz was a well-adjusted fifth-grader earning straight A’s and B’s in school near Fort Hood, Texas.

But shortly after Army Lt. Col. Blaine Radenz left home in June 2008, his 11-year-old son became withdrawn and anxious. His grades at school slipped and his mother noticed mood swings. The child’s longtime pediatrician referred him for counseling.

A psychiatrist at Fort Hood’s Darnall Army Medical Center prescribed the antidepressant Celexa. Daniel also saw a psychologist there. Doctors added to and changed Daniel’s drug regimen, but his problems grew worse, said his mother, Tricia Radenz. Daniel started cutting himself and once used his own blood to write “the end” on a bathroom wall at school. One day in band class, he began hallucinating and ran into the hall, where teachers found him crouched and hitting and scratching his face.

On June 9, 2009, Daniel hanged himself from a bunk bed in his home.

Wyeth Execs Can’t Hide Behind Silence on Antidepressant Data

A lawsuit that alleges Wyeth executives told a series of lies about the antidepressant Pristiq — suggesting that it was a good treatment for post-menopause hot-flashes when they were sitting on study data showing a risk of heart and liver problems — gives new guidance to management on what counts as a false or misleading disclosure to investors.

In the case, the judge ruled that front-loading your investor presentations with a bunch of boilerplate language about “safe-harbor” predictions and “forward-looking statements” that ought to be treated with caution does not allow you to stay silent about negative data that you know will affect the fortunes of your company. (The order was reaffirmed just before Thanksgiving.)

Psychiatrist on Payroll of Glaxo Pleads Guilty to Research Fraud

A psychiatrist on the payroll of GlaxoSmithKline has been sentenced to 13 months in prison after pleading guilty to committing research fraud in trials of the company’s antidepressant Paxil on children. GlaxoSmithKline, manufacturer of Paxil, paid Palazzo $5,000 for every child she enrolled in the study. The case’s significance goes beyond simple research fraud, as Glaxo is now defending itself against charges that for 15 years it deliberately concealed evidence that Paxil increases the risk of suicide in children. Maria Carmen Palazzo is already serving a sentence of 87 months for defrauding Medicare and Medicaid.

Justice to Pharma: “Do the Perp Walk!”

Former GSK counsel is the first target in government’s executive-liability crackdown. Could J&J be next? The US Department of Justice filed criminal charges last week against Lauren Stevens, a former VP and assistant general counsel at GlaxoSmithKline. Going after pharma execs marks a seismic shift in the government’s efforts to stem the tide of fraud and other illegal pharma marketing practices, which a raft of billion-dollar settlements have so far failed to end. Stevens is charged with obstruction of an investigation, concealment and falsification of documents, and making false statements to the FDA in its 2002 investigation of off-label promotion of the antidepressant Wellbutrin for weight loss, an indication for which it has never been approved but has shown some clinical benefit. The DoJ says that it has evidence, in the vast paper and electronic documentation turned over by GSK, showing that Stevens hid and otherwise misled the agency about some 1,000 instances of GSK-paid doctors promoting Wellbutrin for weight loss to other doctors.

U.S. Justice Department Charges Former GlaxoSmithKline VP — A Top Lawyer—with Fraud over Illegal Marketing of Antidepressant Wellbutrin

In a rare move, the Justice Department on Tuesday announced that it had charged a former vice president and top lawyer for the British drug giant GlaxoSmithKline with making false statements and obstructing a federal investigation into illegal marketing of the antidepressant Wellbutrin for weight loss. The indictment grabbed the attention of pharmaceutical executives who have been bracing for a long-promised government crackdown on company officials — rather than the corporations themselves — in drug-fraud cases that have resulted in billions of dollars in fines and payments. “This is absolutely precedent-setting — this is really going to set people’s hair on fire,” said Douglas B. Farquhar, a Washington lawyer who recently presided at a panel on law enforcement during a drug industry conference where federal officials warned they were focusing on individuals. “This is indicative of the F.D.A. and Justice strategy to go after the very top-ranking managing officials at regulated companies.”